What are the indications for octreotide (100 µg/mL)?

Indications for Octreotide (100 mcg/mL)

Octreotide (100 mcg/mL) is FDA-approved for three primary indications: acromegaly (to reduce GH and IGF-1 levels in patients with inadequate surgical response), symptomatic treatment of metastatic carcinoid tumors (to control severe diarrhea and flushing), and treatment of profuse watery diarrhea from VIP-secreting tumors (VIPomas). 1

FDA-Approved Indications

1. Acromegaly

• Used to reduce blood levels of growth hormone (GH) and insulin growth factor-1 (IGF-1) in patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine at maximally tolerated doses 1
• Starting dose: 50 mcg subcutaneously three times daily for initial 2 weeks
• Maintenance dose: 100-500 mcg three times daily based on response 1

2. Carcinoid Tumors (Metastatic)

• For symptomatic treatment where it suppresses or inhibits severe diarrhea and flushing episodes associated with carcinoid syndrome 1
• Dosing: 100-600 mcg daily in 2-4 divided doses during initial 2 weeks 1
• Provides substantial relief of flushing and diarrhea in the majority of patients, though hormone levels are not normalized 2

3. VIPomas (Vasoactive Intestinal Peptide Tumors)

• For treatment of profuse watery diarrhea associated with VIP-secreting tumors 1
• Dosing: 200-300 mcg daily in 2-4 divided doses during initial 2 weeks 1
• Patients with this rare life-threatening syndrome frequently respond dramatically to small doses with cessation of diarrhea 2

Additional Guideline-Supported Indications

4. Glucagonomas

• Improvement reported in patients with the syndrome, particularly for the characteristic necrolytic migratory erythema rash 2
• Important caveat: No indication if patient has no syndrome; circulating glucagon levels unlikely to normalize 2

5. Prevention of Carcinoid Crisis

• In instances of stress (anesthesia, surgical operations, hepatic artery embolization), patients with carcinoid syndrome or even with tumor but without syndrome should receive increased coverage 2
• Dosing: Preferably short-acting octreotide by IV administration (50 mcg/h), administered 12 hours before, during, and 48 hours after procedure 2

6. Tumor Growth Control in Neuroendocrine Tumors

• In patients with clinically significant tumor burden or progressive metastatic NETs, octreotide is recommended to potentially control tumor growth 3
• Based on PROMID study showing median time to tumor progression of 14.3 months vs 6.0 months with placebo 3

7. Acute Variceal Hemorrhage

• Octreotide is the vasoactive drug of choice for managing variceal hemorrhage based on its safety profile 4
• Dosing: 50 mcg IV bolus, followed by continuous IV infusion at 50 mcg/h for 2-5 days 4
• Additional IV boluses can be given in case of ongoing bleeding 4

Important Clinical Considerations

Insulinomas - Use with Extreme Caution

• Only 50% of insulinomas have type II somatostatin receptors 2
• Critical warning: Octreotide can profoundly worsen hypoglycemia by suppressing counterregulatory hormones (growth hormone, glucagon, catecholamines) and can result in fatal complications 5
• Should only be administered to patients whose tumors are Octreoscan-positive 5
• Diazoxide is the preferred treatment for insulinomas 2

Gastrinomas - Limited Role

• The syndrome is adequately controlled with high-dose proton pump inhibitors 2
• No definite added benefit in symptom control by addition of octreotide, though some groups advise it 2

Dosing Considerations

• The 100 mcg/mL concentration is appropriate for starting doses (50-100 mcg subcutaneously 2-3 times daily) 2
• Maximum daily dose can reach 1500 mcg 2
• Dose escalation often needed over time 2
• Biochemical response rates (inhibition of hormone production) seen in 30-70% of patients with symptomatic control in the majority 2

Common Pitfalls to Avoid

• Do not use in insulinomas without confirming Octreoscan positivity - risk of fatal hypoglycemia 5
• Monitor for gallstones and gallbladder dysfunction - common side effect requiring periodic monitoring 2
• Monitor glucose metabolism - both hypoglycemia and hyperglycemia may occur 1
• Monitor thyroid function - hypothyroidism may develop 1
• Rotate injection sites to prevent chronic irritation 1